Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa dose-finding trial of EHP-101 in relapsing multiple sclerosis
2022-000253-92Phase 2Active
- Sponsor
- Emerald Health Pharmaceuticals Inc.
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etrinabdione in multiple sclerosis (MS), sponsored by Emerald Health Pharmaceuticals Inc. Primary endpoint: Incidence and severity of treatment-emergent adverse events. Started Oct 2022; status: active.
02
Drugs
etrinabdione
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2022-000253-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000253-92.